Why choose Spain for immunotherapy?
Access advanced Immunotherapy solutions in trusted clinics from $13,992.
No hidden fees – just official clinic prices. Pay at the clinic for Immunotherapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy journey.
This doctor has experience in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy. They have also been involved in numerous phase 1, 2 and 3 studies in breast and melanoma, which have led to the approval of new drugs in new indications. Their main area of interest lies in immunotherapy for melanoma treatment and patient care. They have participated in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, and Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab. They are a member of the Breast Cancer Unit and Melanoma Unit at the Vall d'Hebron University Hospital and the Vall d'Hebron Institute of Oncology. This doctor is an experienced oncologist with expertise in breast cancer and melanoma treatments, including endocrine therapy, immunotherapy, and patient care. They have been involved in numerous clinical trials leading to the approval of new drugs in new indications.
Dr. Jaume Mora Graupera is a pediatric oncologist specializing in the treatment of neuroblastomas, gliomas, Ewing's sarcomas, and Wilms' tumors. He is the Director of the Hematology Oncology Department and Developmental Tumors Laboratory at Sant Joan De Déu - Barcelona Children’s Hospital. He received his medical degree from the University of Barcelona, went on to complete specialty training in pediatrics and fellowships in pediatric hematology oncology and molecular pathology of pediatric cancer at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in the USA. He has won multiple awards and is a member of various medical organizations.
Professor Bosch is a highly reputed leader in Chronic Lymphocytic Leukemia (CLL) and conducts clinical and basic research on CLL and other lymphoproliferative disorders, focusing on the molecular pathogenesis of CLL and new therapeutic approaches. He has published over 100 articles in prestigious journals and is a professor of haematology at the Vall d'Hebron University Hospital of Barcelona.
When considering Immunotherapy, it’s important to understand the different techniques and which is best suited for you. Here’s a concise comparison of popular options:
Keytruda, a form of immune-based therapy, leverages the body's immune system to target and destroy cancer cells using monoclonal antibodies.
CAR T-cell therapy is a personalized immune system therapy that modifies a patient's T-cells to target and destroy cancer cells.